Sterling/Nycomed
Executive Summary
Sterling obtains option to license all new diagnostic imaging agents produced by Norwegian firm Nycomed over the next ten years. Agreement provides for licensing in U.S., Canada, and other "Sterling markets around the world." Sterling's Omnipaque (iohexol), introduced in 1986, and Amipaque (metrizamide) are both licensed from Nycomed.